Evaluation of Molecular Point-of-Care Testing for Respiratory Pathogens in Children With Respiratory Infections: A Retrospective Case-Control Study

ObjectivesOveruse of antibiotics and antibiotic resistance are global healthcare problems. In pediatric patients with respiratory infections, viral and bacterial etiologies are challenging to distinguish, leading to irrational antibiotic use. Rapid and accurate molecular diagnostic testing methods f...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Nan Shen, Yuanjie Zhou, Yajuan Zhou, Lijuan Luo, Wenjuan Chen, Jing Wang, Ruike Zhao, Li Xie, Qing Cao, Yue Tao, Xi Mo
Formato: article
Lenguaje:EN
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://doaj.org/article/bc4a92ebec7e4f23bfb00fdb72688355
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:bc4a92ebec7e4f23bfb00fdb72688355
record_format dspace
spelling oai:doaj.org-article:bc4a92ebec7e4f23bfb00fdb726883552021-11-19T07:18:11ZEvaluation of Molecular Point-of-Care Testing for Respiratory Pathogens in Children With Respiratory Infections: A Retrospective Case-Control Study2235-298810.3389/fcimb.2021.778808https://doaj.org/article/bc4a92ebec7e4f23bfb00fdb726883552021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fcimb.2021.778808/fullhttps://doaj.org/toc/2235-2988ObjectivesOveruse of antibiotics and antibiotic resistance are global healthcare problems. In pediatric patients with respiratory infections, viral and bacterial etiologies are challenging to distinguish, leading to irrational antibiotic use. Rapid and accurate molecular diagnostic testing methods for respiratory pathogens has been shown to facilitate effective clinical decision-making and guide antibiotic stewardship interventions in the developed regions, but its impacts on pediatric patient care in the developing countries remain unclear.MethodsIn this single-center, retrospective case-control study, we compared demographics, clinical characteristics, especially microbiological findings, and antibiotic usage between pediatric patients with respiratory infection receiving FilmArray Respiratory Panel (FilmArray RP) testing and a matched routine testing control group. Our primary outcome was the duration of intravenous antibiotics treatment (DOT) during hospitalization.ResultsEach group consisted of 346 children with a respiratory infection. In the FilmArray RP testing group, the DOT was shorter than that in the routine testing group (6.41 ± 3.67 days versus 7.23 ± 4.27 days; p = 0.006). More patients in the FilmArray RP testing group de-escalated antibiotic treatments within 72 hours of hospitalization (7.80%, 27/346 versus 2.60%, 9/346; p = 0.002). By contrast, fewer patients in the FilmArray RP testing group had escalated antibiotic treatments between 72 hours and seven days (7.80% versus 14.16%; p = 0.007). The cost of hospitalization was significantly lower in the FilmArray RP testing group ($ 1413.51 ± 1438.01 versus $ 1759.37 ± 1929.22; p = 0.008). Notably, the subgroup analyses revealed that the FilmArray RP test could shorten the DOT, improve early de-escalation of intravenous antibiotics within 72 hours of hospitalization, decline the escalation of intravenous antibiotics between 72 hours and seven days, and reduce the cost of hospitalization for both patient populations with or without underlying diseases.ConclusionsMolecular point-of-care testing for respiratory pathogens could help to reduce intravenous antibiotic use and health care costs of pediatric patients with respiratory infections in developing countries.Nan ShenNan ShenYuanjie ZhouYajuan ZhouLijuan LuoWenjuan ChenJing WangRuike ZhaoLi XieQing CaoYue TaoXi MoFrontiers Media S.A.articlepediatric respiratory infectionmolecular point-of-care testingFilmArray Respiratory Panelantimicrobial stewardshiphealth economicsMicrobiologyQR1-502ENFrontiers in Cellular and Infection Microbiology, Vol 11 (2021)
institution DOAJ
collection DOAJ
language EN
topic pediatric respiratory infection
molecular point-of-care testing
FilmArray Respiratory Panel
antimicrobial stewardship
health economics
Microbiology
QR1-502
spellingShingle pediatric respiratory infection
molecular point-of-care testing
FilmArray Respiratory Panel
antimicrobial stewardship
health economics
Microbiology
QR1-502
Nan Shen
Nan Shen
Yuanjie Zhou
Yajuan Zhou
Lijuan Luo
Wenjuan Chen
Jing Wang
Ruike Zhao
Li Xie
Qing Cao
Yue Tao
Xi Mo
Evaluation of Molecular Point-of-Care Testing for Respiratory Pathogens in Children With Respiratory Infections: A Retrospective Case-Control Study
description ObjectivesOveruse of antibiotics and antibiotic resistance are global healthcare problems. In pediatric patients with respiratory infections, viral and bacterial etiologies are challenging to distinguish, leading to irrational antibiotic use. Rapid and accurate molecular diagnostic testing methods for respiratory pathogens has been shown to facilitate effective clinical decision-making and guide antibiotic stewardship interventions in the developed regions, but its impacts on pediatric patient care in the developing countries remain unclear.MethodsIn this single-center, retrospective case-control study, we compared demographics, clinical characteristics, especially microbiological findings, and antibiotic usage between pediatric patients with respiratory infection receiving FilmArray Respiratory Panel (FilmArray RP) testing and a matched routine testing control group. Our primary outcome was the duration of intravenous antibiotics treatment (DOT) during hospitalization.ResultsEach group consisted of 346 children with a respiratory infection. In the FilmArray RP testing group, the DOT was shorter than that in the routine testing group (6.41 ± 3.67 days versus 7.23 ± 4.27 days; p = 0.006). More patients in the FilmArray RP testing group de-escalated antibiotic treatments within 72 hours of hospitalization (7.80%, 27/346 versus 2.60%, 9/346; p = 0.002). By contrast, fewer patients in the FilmArray RP testing group had escalated antibiotic treatments between 72 hours and seven days (7.80% versus 14.16%; p = 0.007). The cost of hospitalization was significantly lower in the FilmArray RP testing group ($ 1413.51 ± 1438.01 versus $ 1759.37 ± 1929.22; p = 0.008). Notably, the subgroup analyses revealed that the FilmArray RP test could shorten the DOT, improve early de-escalation of intravenous antibiotics within 72 hours of hospitalization, decline the escalation of intravenous antibiotics between 72 hours and seven days, and reduce the cost of hospitalization for both patient populations with or without underlying diseases.ConclusionsMolecular point-of-care testing for respiratory pathogens could help to reduce intravenous antibiotic use and health care costs of pediatric patients with respiratory infections in developing countries.
format article
author Nan Shen
Nan Shen
Yuanjie Zhou
Yajuan Zhou
Lijuan Luo
Wenjuan Chen
Jing Wang
Ruike Zhao
Li Xie
Qing Cao
Yue Tao
Xi Mo
author_facet Nan Shen
Nan Shen
Yuanjie Zhou
Yajuan Zhou
Lijuan Luo
Wenjuan Chen
Jing Wang
Ruike Zhao
Li Xie
Qing Cao
Yue Tao
Xi Mo
author_sort Nan Shen
title Evaluation of Molecular Point-of-Care Testing for Respiratory Pathogens in Children With Respiratory Infections: A Retrospective Case-Control Study
title_short Evaluation of Molecular Point-of-Care Testing for Respiratory Pathogens in Children With Respiratory Infections: A Retrospective Case-Control Study
title_full Evaluation of Molecular Point-of-Care Testing for Respiratory Pathogens in Children With Respiratory Infections: A Retrospective Case-Control Study
title_fullStr Evaluation of Molecular Point-of-Care Testing for Respiratory Pathogens in Children With Respiratory Infections: A Retrospective Case-Control Study
title_full_unstemmed Evaluation of Molecular Point-of-Care Testing for Respiratory Pathogens in Children With Respiratory Infections: A Retrospective Case-Control Study
title_sort evaluation of molecular point-of-care testing for respiratory pathogens in children with respiratory infections: a retrospective case-control study
publisher Frontiers Media S.A.
publishDate 2021
url https://doaj.org/article/bc4a92ebec7e4f23bfb00fdb72688355
work_keys_str_mv AT nanshen evaluationofmolecularpointofcaretestingforrespiratorypathogensinchildrenwithrespiratoryinfectionsaretrospectivecasecontrolstudy
AT nanshen evaluationofmolecularpointofcaretestingforrespiratorypathogensinchildrenwithrespiratoryinfectionsaretrospectivecasecontrolstudy
AT yuanjiezhou evaluationofmolecularpointofcaretestingforrespiratorypathogensinchildrenwithrespiratoryinfectionsaretrospectivecasecontrolstudy
AT yajuanzhou evaluationofmolecularpointofcaretestingforrespiratorypathogensinchildrenwithrespiratoryinfectionsaretrospectivecasecontrolstudy
AT lijuanluo evaluationofmolecularpointofcaretestingforrespiratorypathogensinchildrenwithrespiratoryinfectionsaretrospectivecasecontrolstudy
AT wenjuanchen evaluationofmolecularpointofcaretestingforrespiratorypathogensinchildrenwithrespiratoryinfectionsaretrospectivecasecontrolstudy
AT jingwang evaluationofmolecularpointofcaretestingforrespiratorypathogensinchildrenwithrespiratoryinfectionsaretrospectivecasecontrolstudy
AT ruikezhao evaluationofmolecularpointofcaretestingforrespiratorypathogensinchildrenwithrespiratoryinfectionsaretrospectivecasecontrolstudy
AT lixie evaluationofmolecularpointofcaretestingforrespiratorypathogensinchildrenwithrespiratoryinfectionsaretrospectivecasecontrolstudy
AT qingcao evaluationofmolecularpointofcaretestingforrespiratorypathogensinchildrenwithrespiratoryinfectionsaretrospectivecasecontrolstudy
AT yuetao evaluationofmolecularpointofcaretestingforrespiratorypathogensinchildrenwithrespiratoryinfectionsaretrospectivecasecontrolstudy
AT ximo evaluationofmolecularpointofcaretestingforrespiratorypathogensinchildrenwithrespiratoryinfectionsaretrospectivecasecontrolstudy
_version_ 1718420338172231680